| Literature DB >> 34035401 |
Marie-Pierre Dubé1,2,3, Audrey Lemaçon4,5,6, Amina Barhdadi4,5, Louis-Philippe Lemieux Perreault4,5, Essaïd Oussaïd4,5, Géraldine Asselin4,5, Sylvie Provost4,5, Maxine Sun4,5,6, Johanna Sandoval4,5, Marc-André Legault4,5,7, Ian Mongrain4,5, Anick Dubois4,5, Diane Valois4,5, Emma Dedelis4,5, Jennifer Lousky4,5, Julie Choi4,5, Elisabeth Goulet4, Christiane Savard4, Lea-Mei Chicoine4, Mariève Cossette4,8, Malorie Chabot-Blanchet4,8, Marie-Claude Guertin4,8, Simon de Denus4,5,9, Nadia Bouabdallaoui4, Richard Marchand4, Zohar Bassevitch4,8, Anna Nozza4,8, Daniel Gaudet10, Philippe L L'Allier4, Julie Hussin4,6,7, Guy Boivin11, David Busseuil4, Jean-Claude Tardif12,13.
Abstract
We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 × 10-8) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 × 10-8) in interaction with colchicine (P = 1.19 × 10-5) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.Entities:
Year: 2021 PMID： 34035401 DOI： 10.1038/s41598-021-90365-6
Source DB: PubMed Journal: Sci Rep ISSN： 2045-2322 Impact factor: 4.379